The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity - PubMed
Review
The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity
Gregory M Miller. J Neurochem. 2011 Jan.
Abstract
It is now recognized that trace amine associated-receptor 1 (TAAR1) plays a functional role in the regulation of brain monoamines and the mediation of action of amphetamine-like psychostimulants. Accordingly, research on TAAR1 opens the door to a new avenue of approach for medications development to treat drug addiction as well as the spectrum of neuropsychiatric disorders hallmarked by aberrant regulation of brain monoamines. This overview focuses on recent studies which reveal a role for TAAR1 in the functional regulation of monoamine transporters and the neuronal regulatory mechanisms that modulate dopaminergic activity.
© 2010 The Author. Journal of Neurochemistry © 2010 International Society for Neurochemistry.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1510/3005101/ed962236c131/nihms253643f1.gif)
Left: Depiction of a dopaminergic synaptic terminal that expresses TAAR1. TAAR1 activation triggers cellular signaling events including activation of PKA and PKC that lead to phosphorylation-dependent dopamine efflux via the dopamine transporter and dopamine transporter internalization. In addition, TAAR1 agonists (such as amphetamine, methamphetamine or trace amine) compete with dopamine for reuptake (competitive inhibition). These processes raise extracellular dopamine levels. Bradaia et al (2009) has reported that the TAAR1 antagonist, EPPTB, increases the firing frequency of dopamine neurons, suggesting that TAAR1 either exhibits constitutive activity or is tonically activated by ambient levels of endogenous agonist. These investigators also showed a reduction in firing frequency of dopamine neurons in response to the TAAR1 agonist tyramine. In mouse substantia nigra, Xie et al (2007) observed frequent TAAR1-expressing neurons in the midst of DAT-positive neurons and processes that did not coexpress DAT but that were in approximation to DAT neurons (a previously unpublished image illustrating this proximity is shown in Figure 2). Accordingly, the model presented predicts that TAAR1 agonists decrease the firing frequency of dopamine neurons by activating TAAR1 in adjacent inhibitory neurons, while also increasing extracellular levels of dopamine via both competitive inhibition of reuptake of dopamine as well as by non-competitive, TAAR1-mediated uptake inhibition and promotion of efflux. It is notable that the increased levels of extracellular dopamine may not be highly localized to the dopaminergic synapse, in that the location of dopamine transporters spans the neuron throughout its entire somatodendritic and axonal domains and at terminals resides outside of synaptic active zones, whereas dopamine is released from the somata of substantia nigra neurons by exocytosis in response to neuronal electrical activity (Ciliax et al. 1999; Jaffe et al. 1998). Also, these non-competitive effects are PKA- and PKC-dependent and are attenuated by D2 receptor activation. Right: Depiction of a dopaminergic terminal in a TAAR1 knockout mouse. In the absence of TAAR1, agonists such as amphetamine and methamphetamine do not trigger phosphorylation-dependent dopamine efflux via the dopamine transporter nor dopamine transporter internalization, yet the competitive inhibition of dopamine reuptake (which is TAAR1-independent) by amphetamine still occurs. In the absence of TAAR1, TAAR1 knockout mice show a greater locomotor response to amphetamine and release more dopamine (and norepinephrine) in response to amphetamine than do WT mice. As TAAR1 activation decreases the firing frequency of dopamine neurons, TAAR1 knockout mice may have a higher firing frequency which is not decreased in response to amphetamine. The collective effects of these processes may result in the higher synaptic dopamine levels induced by amphetamine in TAAR1 knockout mice, and also explain the enhanced behavioral response to amphetamine.
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1510/3005101/2627c192348a/nihms253643f2.gif)
In the double-label immunofluorescent image (right), neurons are present that express either TAAR1 (green) or DAT (red), but not both. TAAR1 staining is observed in two neurons (N) with apparent intracellular localization, as well as in an epithelial cell (E) where it appears to be localized to the extracellular plasma membrane. Note the proximity of TAAR1-positive neurons to two dopamine neurons (D). Nuclei (blue); red blood cells in endothelial cell (purple). Smaller images of individual channels, including TAAR1 (green), DAT (red), and differential interference contract (DIC), are shown on the left side of the larger composite panel. Micrometer bar = 20 microns. Methods can be found in Xie et al., 2007.
Similar articles
-
Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM. Xie Z, et al. J Pharmacol Exp Ther. 2007 Apr;321(1):116-27. doi: 10.1124/jpet.106.116863. Epub 2007 Jan 18. J Pharmacol Exp Ther. 2007. PMID: 17234900
-
Trace amine-associated receptor 1 as a monoaminergic modulator in brain.
Xie Z, Miller GM. Xie Z, et al. Biochem Pharmacol. 2009 Nov 1;78(9):1095-104. doi: 10.1016/j.bcp.2009.05.031. Epub 2009 May 29. Biochem Pharmacol. 2009. PMID: 19482011 Free PMC article.
-
Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases.
Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Schwartz MD, et al. Expert Opin Ther Targets. 2018 Jun;22(6):513-526. doi: 10.1080/14728222.2018.1480723. Epub 2018 Jun 5. Expert Opin Ther Targets. 2018. PMID: 29798691 Review.
-
Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants.
Jayanthi LD, Ramamoorthy S. Jayanthi LD, et al. AAPS J. 2005 Oct 27;7(3):E728-38. doi: 10.1208/aapsj070373. AAPS J. 2005. PMID: 16353949 Free PMC article. Review.
Cited by
-
Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T. Wen X, et al. Signal Transduct Target Ther. 2022 Aug 28;7(1):298. doi: 10.1038/s41392-022-01149-x. Signal Transduct Target Ther. 2022. PMID: 36031641 Free PMC article. Review.
-
Neural vulnerability factors for obesity.
Stice E, Burger K. Stice E, et al. Clin Psychol Rev. 2019 Mar;68:38-53. doi: 10.1016/j.cpr.2018.12.002. Epub 2018 Dec 19. Clin Psychol Rev. 2019. PMID: 30587407 Free PMC article. Review.
-
Aleksandrov AA, Knyazeva VM, Volnova AB, Dmitrieva ES, Korenkova O, Espinoza S, Gerasimov A, Gainetdinov RR. Aleksandrov AA, et al. Neurotox Res. 2018 Oct;34(3):442-451. doi: 10.1007/s12640-018-9902-6. Epub 2018 May 1. Neurotox Res. 2018. PMID: 29713997
-
Kundu D, Zhu A, Kim E, Paudel S, Jang CG, Lee YS, Kim KM. Kundu D, et al. Biomol Ther (Seoul). 2023 Jan 1;31(1):108-115. doi: 10.4062/biomolther.2022.047. Epub 2022 Sep 13. Biomol Ther (Seoul). 2023. PMID: 36098044 Free PMC article.
-
Frati P, Kyriakou C, Del Rio A, Marinelli E, Vergallo GM, Zaami S, Busardò FP. Frati P, et al. Curr Neuropharmacol. 2015 Jan;13(1):5-11. doi: 10.2174/1570159X13666141210221750. Curr Neuropharmacol. 2015. PMID: 26074739 Free PMC article. Review.
References
-
- Altar CA, Wasley AM, Martin LL. Autoradiographic localization andpharmacology of unique [3H]tryptamine binding sites in rat brain. Neuroscience. 1986;17:263–273. - PubMed
-
- Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, Ramsey AJ, Violin JD, Lefkowitz RJ, Caron MG, Gainetdinov RR. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol. 2008;74:585–594. - PMC - PubMed
-
- Bergman J, Yasar S, Winger G. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology. 2001;159:21–30. - PubMed
-
- Berry MD. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem. 2004;90:257–271. - PubMed
-
- Biel JH. Structure-activity relationships of amphetamine and derivatives. In: Costa E, Garratini S, editors. Proc International Symposium on Amphetamines and Related Compounds. Raven Press; New York, USA: 1970. pp. 3–19.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases